News
Eli Lilly (LLY) inks a licensing agreement with Alchemab to jointly develop an ALS drug in a $415M deal. Read more here.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback